Oral Anticoagulant Safety, Apixaban, Statins and VTE According to a recent report from the Institute of Safe Medication practices (ISMP), FDA received 34,765 adverse drug event reports for oral anticoagulants in 2015. Regs, robbery responses among top “pharmacy gamechangers” for 2016 August 10, 2016 By Howard Larkin The issues of most concern to pharmacists, outlined at McKesson’s ideaShare 2016. Fall-related ICH incidence in elderly on warfarin A study of nearly 32,000 aging veterans revealed the unsuspected vulnerability of this population. The expanding role of direct oral anticoagulants in the management of thromboembolic disease The goal of this program for pharmacists and technicians is to review the treatment of venous thromboembolism with the class of medications known as direct oral anticoagulants. Pre-op anticoagulation reduces VTE risk in cancer patients Researchers found that rates of DVT and PE were significantly lower among patients who received preoperative chemoprophylaxis than in those who did not. Andexanet quickly reverses factor Xa inhibitor activity for DOACs Andexanet alpha is designed to reverse the anticoagulant effects of factor Xa inhibitors. How to identify AF patients at low stroke risk In a presentation at the 2015 AHA Fall Conference, Daniel E. Singer, MD, spoke about identifying patients with an increased bleeding risk with the long-term use of oral anticoagulants and whether or not there is a benefit in those cases. Renal function decline common in patients treated with DOACs Deterioration of renal function and an increase in related adverse events is not unusual in patients treated with direct oral anticoagulants.